# Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

> **NCT00003966** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 151 (actual)

## Conditions studied

- Veno-occlusive Disease

## Interventions

- **DRUG:** defibrotide

## Key facts

- **NCT ID:** NCT00003966
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2006-02
- **Final completion:** 2006-04
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2017-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003966, "Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*